Filtered By:
Source: Thrombosis Research
This page shows you your search results in order of relevance. This is page number 14.
Order by Relevance | Date
Total 221 results found since Jan 2013.
Recovery from acute kidney injury in patients with pulmonary embolism: A single-center study
Pulmonary embolism (PE) ranks as the third most common cardiovascular death after coronary artery disease and stroke [1] and, the second leading cause of death after cancer among cancer patients [2]. Acute Kidney Injury (AKI), defined as an abrupt decrease in kidney function, is associated with adverse short-term and long-term outcomes even in the case of mild and reversible AKI [3]. One-third of patients with PE develop AKI and are at increased risk for bleeding and mortality compared with patients without AKI [4].
Source: Thrombosis Research - January 14, 2021 Category: Hematology Authors: Martin Murgier, L éa Fouillet, Edouard Ollier, Adel Merah, Nathalie Moulin, Sandrine Accassat, Cécile Duvillard, Elodie De Magalhaes, Patrick Mismetti, Manuel Monreal, Laurent Bertoletti Tags: Letter to the Editors-in-Chief Source Type: research
Peak plasma rivaroxaban levels in patients weighing 120 kg or greater
Direct oral anticoagulants (DOACs) have become the drug of choice, increasingly replacing traditional vitamin K antagonists (VKA) for stroke prevention in atrial fibrillation (AF) and in the treatment of venous thromboembolism (VTE) due to their advantages of fixed dosing and no requirement for drug monitoring. Furthermore, their use is expanding into the ischemic heart disease population [1]. However, there is ongoing concern regarding their use in those weighing ≥120 kg or who have a body mass index (BMI) ≥ 40 due to limited representation of this patient group in the phase 3 DOAC trials [2,3].
Source: Thrombosis Research - February 17, 2021 Category: Hematology Authors: Jameel Abdulrehman, Rita Selby, Raed A. Joundi, Erik Yeo Tags: Letter to the Editors-in-Chief Source Type: research
Outcomes in patients with acute pulmonary embolism and patent foramen ovale: Findings from the RIETE registry
An increased risk of ischemic stroke in patients with acute pulmonary embolism (PE) and patent foramen ovale (PFO) was reported but few data exist regarding prognostic outcomes of those patients.
Source: Thrombosis Research - March 7, 2021 Category: Hematology Authors: K. Lacut, E. Le Moigne, F. Couturaud, C. Font, F.J. V ázquez, I. Cañas, J.A. Díaz-Peromingo, A. Gil-Díaz, E. Bucherini, M. Monreal, the RIETE investigators Tags: Full Length Article Source Type: research
5-year outcomes from rivaroxaban therapy in atrial fibrillation: Results from the Dresden NOAC Registry
Following successful phase-III trials, direct oral anticoagulants such as rivaroxaban have largely replaced warfarin for stroke prevention in atrial fibrillation (SPAF). However, data from randomized trials should be confirmed in unselected cohorts.
Source: Thrombosis Research - March 7, 2021 Category: Hematology Authors: Luise Tittl, Sandra Marten, Christiane Naue, Jan Beyer-Westendorf Tags: Full Length Article Source Type: research
Peak plasma rivaroxaban levels in patients weighing 120 kg or greater
Direct oral anticoagulants (DOACs) have become the drug of choice, increasingly replacing traditional vitamin K antagonists (VKA) for stroke prevention in atrial fibrillation (AF) and in the treatment of venous thromboembolism (VTE) due to their advantages of fixed dosing and no requirement for drug monitoring. Furthermore, their use is expanding into the ischemic heart disease population [1]. However, there is ongoing concern regarding their use in those weighing ≥120 kg or who have a body mass index (BMI) ≥ 40 due to limited representation of this patient group in the phase 3 DOAC trials [2,3].
Source: Thrombosis Research - February 17, 2021 Category: Hematology Authors: Jameel Abdulrehman, Rita Selby, Raed A. Joundi, Erik Yeo Tags: Letter to the Editors-in-Chief Source Type: research
Not all patent foramen ovales are alike!
We read with great interest the elegant investigation by Lacut et al., based on RIETE registry, demonstrating that patent foramen ovale (PFO) in patients with acute pulmonary embolism (PE) is under-diagnosed and associated with a higher risk of ischemic stroke compared to those without PFO [1]. to Although the results of this study are interesting and a significant contribution to the management of acute PE, the role of PFO in such study population should be cautiously considered since the study did not provide any anatomical and/or functional PFO characterization.
Source: Thrombosis Research - May 5, 2021 Category: Hematology Authors: Gianluca Rigatelli, Marco Zuin Tags: Letter to the Editors-in-Chief Source Type: research
Warfarin anticoagulation in the Covid-19 pandemic: Telephone-based management at a regional hematology outpatient center in Joinville, Brazil
Oral anticoagulation (OA) is a well-established therapeutic approach for prevention of cardioembolic stroke and venous thromboembolism [1]. Adequate OA is a key element in reducing the high social burden, morbidity and mortality associated with cardiovascular diseases [2 –4]. In January 2020, the World Health Organization (WHO) declared COVID-19 a public health emergency of international concern. Since then, the strategy of social distancing has been adopted in most countries, with varying degrees of restriction and compliance.
Source: Thrombosis Research - July 9, 2021 Category: Hematology Authors: Kendra Lys Calixto Machado, Suzana Tanquella da Rosa, Soraya Dobner, Ivan Schneider Boettcher, Gilberto Comaru Pasqualotto, Adelina Elisabeth Lehmkuhl Lopes, Tain á de Araújo, Lysandra Patricia Luchtenberg Bolduan, Maria Daniela Holthausen Perico Colomb Tags: Letter to the Editors-in-Chief Source Type: research
Left atrial appendage occlusion for management of atrial fibrillation in persons with hemophilia
Due to advancements in hemophilia care, the overall life expectancy of persons with hemophilia is almost approaching that of the general population [1]. As a result, a growing population of elderly hemophilia patients is now prone to the same age-related cardiovascular comorbidities, such as coronary artery disease (CAD) and atrial fibrillation (AF) [2,3]. The management of AF is a challenge as antithrombotic therapy, the standard of care, is usually contraindicated in persons with hemophilia. Left atrial appendage occlusion (LAAO) is an alternative option for stroke prevention in patients with AF with a contraindication t...
Source: Thrombosis Research - August 4, 2021 Category: Hematology Authors: Ming Y. Lim, Mouhamed Yazan Abou-Ismail Tags: Letter to the Editors-in-Chief Source Type: research
Novel prenatal diagnosis of protein C deficiency and primary prophylaxis with protein C concentrate
Protein C deficiency (PCD) is a rare inherited thrombophilia with high morbidity and mortality. Protein C plays an important role in the coagulation cascade by inactivating factors V and VIII, which then decreases thrombin production. In the absence of protein C, these pro-coagulant factors proceed unchecked, causing a hypercoagulable state. PCD may manifest with early and severe clinical complications, including purpura fulminans, disseminated intravascular coagulation, vitreal vein thrombosis resulting in blindness, and arterial ischemic stroke [1].
Source: Thrombosis Research - October 19, 2021 Category: Hematology Authors: Alexandra Prosser, Lauren Amos, Mukta Sharma Tags: Full Length Article Source Type: research
Serum thromboxane B2 but not soluble P-selectin levels identify ischemic stroke patients with persistent platelet reactivity while on aspirin therapy
Aspirin non-response due to persistent platelet reactivity has been associated with adverse vascular events. Light transmission aggregometry (LTA), the ‘gold standard’ for measuring the platelet response to aspirin therapy, is a cumbersome procedure and a simple and reliable alternative is required. Our aim was to explore whether serum thromboxane B2 (sTXB2) and soluble P-selectin can be used to identify patients who are at risk of increased pl atelet reactivity while on aspirin.
Source: Thrombosis Research - October 28, 2021 Category: Hematology Authors: Pandarisamy Sundaravadivel, Rita Christopher, Nitin C. Ramanujam, Sadanandavalli Retnaswami Chandra Tags: Full Length Article Source Type: research
Fibrin to von Willebrand factor ratio in arterial thrombi is associated with plasma levels of inflammatory biomarkers and local abundance of extracellular DNA
The composition of thrombi determines their structure, mechanical stability, susceptibility to lysis, and consequently, the clinical outcome in coronary artery disease (CAD), acute ischemic stroke (AIS), and peripheral artery disease (PAD). Fibrin forms the primary matrix of thrombi intertwined with DNA, derived from neutrophil extracellular traps (NETs), and von Willebrand factor (VWF) bridging DNA and platelets. Here we examined the relative content of fibrin, DNA and VWF in thrombi and analyzed their interrelations and quantitative associations with systemic biomarkers of inflammation and clinical characteristics of the patients.
Source: Thrombosis Research - November 17, 2021 Category: Hematology Authors: Erzs ébet Tóth, László Beinrohr, István Gubucz, László Szabó, Kiril Tenekedjiev, Natalia Nikolova, Anikó I. Nagy, László Hidi, Péter Sótonyi, István Szikora, Béla Merkely, Krasimir Kolev Source Type: research
To aPTT or not to aPTT: Evaluating the optimal monitoring strategy for unfractionated heparin
Anticoagulation is widely used in the inpatient setting for various indications for both surgical and medical patients including stroke prevention in non-valvular atrial fibrillation, prevention of venous thromboembolism in post-surgical patients, management of acute coronary syndromes, and treatment of acute thrombosis. For patients with acute thrombosis, anticoagulation is the key therapy to stabilize the thrombus, prevent extension, and to prevent development of new thrombosis while risk factors are present [1].
Source: Thrombosis Research - November 21, 2021 Category: Hematology Authors: Nathan T. Connell, Katelyn W. Sylvester Tags: Editorial Source Type: research
Coagulation factors XI and XII as possible targets for anticoagulant therapy
In this review, we give an overview over observational and experimental studies supporting factors XI and XII as targets for anticoagulant therapy. The majority of observational studies on FXI report low concentrations of FXI to be protective against ischemic stroke and venous thrombosis. There is also extensive evidence from experimental and animal studies supporting FXI inhibition as a target for anticoagulant therapy, alone or in combination with other antithrombotic treatments. Four Phase 2 clinical trials on patients undergoing total knee arthroplasty showed non-inferiority or superiority of FXI inhibition compared to...
Source: Thrombosis Research - April 23, 2022 Category: Hematology Authors: Karsten Engseth Kluge, Ingebj ørg Seljeflot, Harald Arnesen, Torstein Jensen, Sigrun Halvorsen, Ragnhild Helseth Source Type: research
PO-11: Risk of major bleeding in cancer patients with ischemic stroke treated with thrombolysis
Source: Thrombosis Research - May 1, 2022 Category: Hematology Authors: N. Skajaa, K. Adelborg, F.S. Troelsen, C.H. Fuglsang, E. Horv áth-Puhó, H.T. Sørensen Tags: Posters Source Type: research
OC-12: Stroke and risk of cancer: a Danish population-based cohort study
Source: Thrombosis Research - May 1, 2022 Category: Hematology Authors: N. Skajaa, K. Veres, F.S. Troelsen, J.D. Petersen, K. Adelborg, H.T. S ørensen Tags: Oral Communications Source Type: research
